Brian Cey, NP
Nurse Practitioner · Eagle, IDNPI 1659939031
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,246, more than ten times the $34 reported in 2021. Among nurse practitioner clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$411
- Novo Nordisk$359
- AbbVie$231
- GSK$172
- Amgen$160
- Exact Sciences$133
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,650100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $411 |
| Novo Nordisk | 22 | $359 |
| AbbVie | 10 | $231 |
| GSK | 9 | $172 |
| Amgen | 8 | $160 |
| Exact Sciences | 5 | $133 |
| Bayer | 4 | $110 |
| Lilly USA, LLC | 7 | $108 |
| Novartis | 5 | $101 |
| Medtronic | 4 | $81 |
| Xeris Pharmaceuticals, Inc. | 4 | $80 |
| Dexcom, Inc. | 3 | $76 |
| Astellas Pharma US Inc | 3 | $76 |
| AstraZeneca | 3 | $58 |
| Boehringer Ingelheim | 2 | $44 |
| Stryker | 1 | $34 |
| Johnson & Johnson | 2 | $33 |
| Acadia Pharmaceuticals Inc | 1 | $30 |
| Sonex Health, Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Shield Therapeutics Inc | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| Edwards Lifesciences | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Dynavax Technologies Corporation | 2 | $16 |
| Halozyme Inc | 1 | $16 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| Vertex | 1 | $14 |
How this compares
$2,650 in reported general payments places this provider in the 90th percentile of 570 nurse practitioner providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 22 | $37,168 |
| FarxigaDapagliflozin Propanediol | 21 | $32,791 |
| OzempicSemaglutide | 15 | $24,227 |
| Bydureon BciseExenatide Microspheres | 11 | $18,581 |
| EliquisApixaban | 15 | $17,147 |
| Levothyroxine Sodium | 178 | $2,157 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,634 |
| Gabapentin | 65 | $1,566 |
| Atorvastatin Calcium | 133 | $1,259 |
| Potassium Chloride | 24 | $1,151 |
| Losartan Potassium | 137 | $970 |
| Duloxetine Hcl | 31 | $897 |
| Metformin Hcl ErMetformin Hcl | 63 | $877 |
| Lisinopril | 82 | $723 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $44 | $37,16822 claims |
| AstraZenecaFarxiga | $58 | $32,79121 claims |
| Novo NordiskOzempic | $359 | $24,22715 claims |
| PfizerEliquis | $411 | $17,14715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 570 nurse practitioner providers in Idaho.
Other nurse practitioner in Eagle
- Kathleen CliffordBoise$119K
- Alissa HelvikCoeur D Alene$93K
- Amanda ThompsonIdaho Falls$67K
- Micalena PerkinsBurley$44K
- Tosha JohnsonNampa$26K
- Loreen NugentBoise$20K
- Rachel RyanMeridian$19K
- Stephanie HartPost Falls$18K
- Joshua ScovilleTwin Falls$12K
- John PilcherBoise$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.